you are viewing a single comment's thread.
In Mapp's case, good thing..fda knows the drug mapp uses.
Means the FDA doesn't think it's a controversial call. Re approval, this is neither a positive nor a negative. But usually if more data, etc. will be required, or there is controversy, there is a Review panel.